Modality
Nanobody
MOA
PRMT5i
Target
Cl18.2
Pathway
T-cell
ET
Development Pipeline
Preclinical
~Oct 2017
→ ~Jan 2019
Phase 1
Apr 2019
→ Nov 2027
Phase 1Current
NCT04343292
2,453 pts·ET
2019-04→2027-11·Not yet recruiting
NCT07029687
2,327 pts·ET
2019-10→2027-02·Not yet recruiting
4,780 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-09-256mo awayEnrollment Complete· ET
2027-02-2611mo awayInterim· ET
2027-11-151.6y awayInterim· ET
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P1
Not yet…
P1
Not yet…
Catalysts
Enrollment Complete
2026-09-25 · 6mo away
ET
Interim
2027-02-26 · 11mo away
ET
Interim
2027-11-15 · 1.6y away
ET
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04343292 | Phase 1 | ET | Not yet recr... | 2453 | HAM-D |
| NCT07029687 | Phase 1 | ET | Not yet recr... | 2327 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-8550 | Roche | Approved | BCL-2 | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 |